Tianyuan Bio-Pharmaceutical

Zhejiang Tianyuan Bio-Pharmaceutical is a prominent Chinese biopharmaceutical company specialized in the development, manufacturing, and commercialization of human vaccines. Founded in 1994, the company established itself as a leader in the Chinese vaccine market with a portfolio targeting influenza, meningitis, and hemorrhagic fever. The company gained significant international attention when Novartis acquired an 85% stake in 2011 to anchor its vaccines business in China. Following a major asset swap in 2015, the company transitioned to GSK's ownership before being divested to a Chinese investment group in 2018. Today, it continues to operate as a key manufacturer of essential vaccines for the domestic Chinese market, maintaining high-standard GMP facilities in Hangzhou.